IntroductionGene mutations that define distinct biologic subsets of acute myeloid leukemia (AML) were integrated into the recently revised diagnostic (WHO) and prognostic (ELN 2022) models. Mutations in SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2 now...
Background: In version 1 (v1) of the NCRI AML18 trial we demonstrated that a fractionated, schedule of Gemtuzumab ozogamicin (GO) combined with daunorubicin/cytarabine (DAGO2) reduced Measurable Residual Disease (MRD) and improved overall survival (OS) in older acute...
Introduction: Molecular follow-up (FU) of measurable residual disease (MRD) by real-time quantitative PCR (qPCR) is well established in AML patients (pts) with NPM1mut, RUNX1::RUNX1T1, or CBFB::MYH11 transcripts. Pts who fail to achieve molecular complete remission...
Introduction:Venetoclax (Ven) plus intensive chemotherapy is a promising therapy for patients (pts) with untreated acute myeloid leukemia (AML) but has not been extensively studied in combination with the “7+3” regimen. In a phase 1b study at a tertiary...
Introduction: Venetoclax (VEN) combined with Azacytidine (AZA) or Low dose cytarabine (LDAC) is the standard of care for patients (pts) with newly diagnosed acute myeloid leukemia (AML) aged ≥ 75 yrs or not candidates to intensive treatment. However, some pts,...
Introduction: Liposomal cytarabine and daunorubicin (CPX-351) is an approved therapy for newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, for which it showed improved response rate and overall survival (OS) up to 5 years compared with...
Recent Comments